Article
Oncology
Won Kil Lee, Jisoo Myong, Eunbin Kwag, Younmin Shin, Ji Woong Son, Byong Chul Yoo, Byoung-Soo Kim, Hwa-Seung Yoo, Jeong June Choi
Summary: This study compared the changes in blood metabolites in NSCLC patients before and after taking erlotinib and found that the levels of 1005 substances changed. The study also discovered peak area differences in 5539 substances based on the presence of skin rash. The results suggest that erlotinib can alter carbohydrate, amino acid, and vitamin metabolic pathways.
INTEGRATIVE CANCER THERAPIES
(2023)
Editorial Material
Oncology
Sun Min Lim, Chang Gon Kim, Byoung Chul Cho
Summary: Treatment resistance to targeted agents is a significant challenge in cancer therapy and is also observed in EGFR-mutant NSCLC. Current efforts focus on delaying or overcoming acquired resistance, and targeting compensatory feedback loops along with oncogenic signaling pathways holds promise for improved outcomes.
Article
Oncology
Fabrice Barlesi, Pascale Tomasini, Maryam Karimi, Stefan Michiels, Judith Raimbourg, Catherine Daniel, Henri Janicot, Anne Madroszyk, Clarisse Audigier-Valette, Elisabeth Quoix, Julien Mazieres, Denis Moro-Sibilot, Eric Dansin, Olivier Molinier, Hugues Morel, Eric Pichon, Alexis Cortot, Josiane Otto, Francois Chomy, Pierre-Jean Souquet, Nicolas Cloarec, Etienne Giroux-Leprieur, Ivan Bieche, Ludovic Lacroix, Sandrine Boyault, Valery Attignon, Isabelle Soubeyran, Alain Morel, Alicia Tran-Dien, Alexandra Jacquet, Filippo Gustavo Dall'Olio, Marta Jimenez, Jean-Charles Soria, Benjamin Besse
Summary: Targeted therapies and immune checkpoint blockers have revolutionized the treatment of non-small cell lung cancer. This study investigated the use of targeted therapies and immune checkpoint blockers as maintenance therapy based on molecular characterization. The results showed no significant differences in progression-free survival between targeted therapies and standard-of-care, and immune checkpoint blockers showed enhanced benefits in patients with PD-L1 >= 1%.
CLINICAL CANCER RESEARCH
(2022)
Article
Pharmacology & Pharmacy
A. S. Pal, M. Bains, A. Agredo, A. L. Kasinski
Summary: Lung cancer is a major cause of cancer-related deaths, and overcoming resistance to EGFR inhibitors is crucial in the treatment of non-small cell lung cancer. This study identifies the important role of microRNAs in driving resistance to EGFR inhibitors in non-small cell lung cancer cells.
BIOCHEMICAL PHARMACOLOGY
(2021)
Article
Multidisciplinary Sciences
Mari Tone, Kota Iwahori, Takayuki Shiroyama, Shinji Futami, Yujiro Naito, Kiyoharu Fukushima, Kotaro Miyake, Shohei Koyama, Haruhiko Hirata, Izumi Nagatomo, Hisashi Wada, Yoshito Takeda, Atsushi Kumanogoh
Summary: Minocycline administration in NSCLC patients treated with first-line EGFR-TKIs was found to correlate with longer PFS and OS, independent of skin rash. This retrospective analysis suggests that minocycline may have a positive impact on the treatment outcomes of EGFR-mutant NSCLC patients.
SCIENTIFIC REPORTS
(2023)
Article
Biochemistry & Molecular Biology
Przemyslaw Bieganski, Martina Godel, Chiara Riganti, Daniel Fabio Kawano, Joanna Kopecka, Konrad Kowalski
Summary: A library of 1,4- and 1,5-triazole ferrocenyl derivatives of erlotinib were synthesized and their anticancer activity was studied against erlotinib-sensitive and erlotinib-resistant lung cancer cells. Among the compounds investigated, two isomers showed superior activity against erlotinib-resistant cells, with a mechanism of action different from erlotinib.
BIOORGANIC CHEMISTRY
(2022)
Article
Biology
Xiaolong Tang, Lizhi Cheng, Guo Li, Yong-Ming Yan, Fengting Su, Dan-Ling Huang, Shuping Zhang, Zuojun Liu, Minxian Qian, Ji Li, Yong-Xian Cheng, Baohua Liu
Summary: The small molecule compound D6 demonstrates promising efficacy in treating EGFR-TKI resistant NSCLC by targeting the protein-protein interaction between HSP90 and T790M-EGFR, offering a potential alternative strategy to overcome drug resistance.
COMMUNICATIONS BIOLOGY
(2021)
Article
Engineering, Biomedical
Duo Wang, Jun Zhou, Weimin Fang, Cuiqing Huang, Zerong Chen, Meng Fan, Ming-Rong Zhang, Zeyu Xiao, Kuan Hu, Liangping Luo
Summary: In this study, a multifunctional superparamagnetic nanotheranostic agent was developed to enhance the efficacy of Erlotinib in EGFR-wt NSCLC. The nanoparticles co-delivered Erlotinib and a VEGF inhibitor (Bev) to EGFR-wt tumors, inhibiting tumor growth and promoting vascular normalization. The tumor engagement of nanoparticles and vascular normalization could be tracked by MRI.
BIOACTIVE MATERIALS
(2022)
Article
Nanoscience & Nanotechnology
Mei Cong, Houjun Pang, Guangxing Xie, Feifei Li, Chunxiao Li, Hao Sun, Shaoyou Yang, Weidong Zhao
Summary: This study presents a self-assemble amphiphilic molecule-based nanoformulation of erlotinib as an effective nanodrug for cancer treatment. The nanodrug exhibits a high drug loading, well-defined structure, small size, and effective tumor accumulation and internalization. Compared to free erlotinib, the erlotinib nanodrug shows significantly better anticancer activity in vitro and in vivo, with good tolerability. This novel nanomedicine shows promise as a therapeutic candidate for cancer treatment and highlights the potential use of amphiphilic molecules for nanodrug preparation.
INTERNATIONAL JOURNAL OF NANOMEDICINE
(2023)
Article
Pharmacology & Pharmacy
Amineh Ghaderi, Mohammad-Ali Okhovat, Jemina Lehto, Luigi De Petris, Ehsan Manouchehri Doulabi, Parviz Kokhaei, Wen Zhong, Georgios Z. Rassidakis, Elias Drakos, Ali Moshfegh, Johan Schultz, Thomas Olin, Anders Osterborg, Hakan Mellstedt, Mohammad Hojjat-Farsangi
Summary: This study evaluated the expression of ROR1 in NSCLC patients and the cytotoxic effects of a small molecule ROR1 inhibitor in NSCLC cell lines. ROR1 was overexpressed in non-squamous and squamous carcinomas, as well as neuroendocrine tumors. The ROR1 inhibitor dephosphorylated ROR1 and induced apoptosis, and also inhibited the proliferation and migration of NSCLC cells. The combination of the ROR1 inhibitor and EGFR inhibitor showed a synergistic apoptotic effect.
Article
Pharmacology & Pharmacy
Cong Xu, Ze-Bo Jiang, Le Shao, Zi-Ming Zhao, Xing-Xing Fan, Xinbing Sui, Li-Li Yu, Xuan-Run Wang, Ruo-Nan Zhang, Wen-Jun Wang, Ya-Jia Xie, Yi-Zhong Zhang, Xiao-Wen Nie, Chun Xie, Ju-Min Huang, Jing Wang, Jue Wang, Elaine Lai-Han Leung, Qi-Biao Wu
Summary: This study found that the combination of ll-elemene and erlotinib induced ferroptosis and enhanced the sensitivity to EGFR-TKIs in EGFR-TKI-resistant lung cancer patients.
PHARMACOLOGICAL RESEARCH
(2023)
Review
Oncology
Bharathi Muthusamy, Pradnya D. Patil, Nathan A. Pennell
Summary: Despite advancements in treatment for advanced non-small cell lung cancer (NSCLC), recurrence rates remain high for patients with resectable early-stage disease. Immune checkpoint inhibitors and targeted therapies show promise for improving survival outcomes when used in the curative setting instead of advanced stage treatment.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
(2022)
Article
Pharmacology & Pharmacy
Edward B. Garon, Paige Brodrick
Summary: The tyrosine kinase receptor mesenchymal epithelial transition (MET) plays a role in non-small cell lung cancer (NSCLC) and abnormal activation may contribute to oncogenesis. MET overexpression, amplification, or mutation as therapeutic targets are of interest, particularly MET exon 14 skipping mutations which have shown significant responses to MET inhibitors.
Article
Multidisciplinary Sciences
Chie Morita, Tatsuya Yoshida, Masayuki Shirasawa, Ken Masuda, Yuji Matsumoto, Yuki Shinno, Shigehiro Yagishita, Yusuke Okuma, Yasushi Goto, Hidehito Horinouchi, Noboru Yamamoto, Noriko Motoi, Yasushi Yatabe, Yuichiro Ohe
Summary: Patients with Exon20ins mutations and major mutations had similar clinical characteristics, but Exon20ins patients had less satisfactory clinical outcomes compared to M-mut patients.
SCIENTIFIC REPORTS
(2021)
Article
Multidisciplinary Sciences
Chia- Shen, Chi-Lu Chiang, Tsu-Hui Shiao, Yung-Hung Luo, Heng-Sheng Chao, Hsu-Ching Huang, Chao-Hua Chiu
Summary: Detection of driver gene mutations is crucial in advanced NSCLC. The cobas EGFR mutation test has limitations due to its primer design, while next-generation sequencing-based assay provides a higher mutation detection coverage. Comprehensive genomic profiling can identify EGFR mutations missed by the cobas test and offers significant benefits to patients with NSCLC.
SCIENTIFIC REPORTS
(2022)
Review
Critical Care Medicine
Antonio Messina, Federico Villa, Maurizio Cecconi
Summary: This review examines the hemodynamic approach to different phases of acute ischemic stroke, subarachnoid hemorrhage, and intracerebral hemorrhage, and suggests an integrated management strategy.
CURRENT OPINION IN CRITICAL CARE
(2022)
Article
Medicine, General & Internal
Federico Villa, Aurora Di Filippo, Andrea Pierantozzi, Armando Genazzani, Antonio Addis, Gianluca Trifiro, Agnese Cangini, Giovanni Tafuri, Daniela Settesoldi, Francesco Trotta
Summary: This study analyzed the prices of orphan drugs and their correlation with the epidemiology of rare diseases in Italy from 2014 to 2019. The results showed that the price of orphan drugs is not influenced by the rarity of the disease, and the sales volume does not correlate with the epidemiology or therapy cost.
FRONTIERS IN MEDICINE
(2022)
Article
Behavioral Sciences
Francesca Santicchia, Lucas Armand Wauters, Claudia Tranquillo, Federica Villa, Ben Dantzer, Rupert Palme, Damiano Preatoni, Adriano Martinoli
Summary: Free-living animals use physiological and behavioural responses to cope with environmental stressors. These responses are integrated within a coping style, which may change when exposed to human-induced rapid environmental change. This study found that an invasive alien species disrupts the behavioural syndrome of a native species, but does not influence its coping style.
HORMONES AND BEHAVIOR
(2022)
Article
Medicine, General & Internal
Francesca Arizio, Alessio Bonardi, Diego Cortinovis, Antonio Costanzo, Adriano Cristinziano, Lina Delle Monache, Raffaele Landolfi, Maddalena Lettino, Fabrizio Luppi, Teresa Petrangolini, Domenica Tassielli
Summary: The R.Evolution project aimed to identify and address the main challenges in conducting clinical research in Italy, with a focus on study feasibility, authorization procedures, operational aspects and patient management. The project identified key issues such as lack of awareness of clinical research value, shortage of trained workforce and complexity of protocols/administrative procedures.
CURRENT MEDICAL RESEARCH AND OPINION
(2022)
Article
Biochemistry & Molecular Biology
Barbara Cardinali, Giuseppa De Luca, Roberta Tasso, Simona Coco, Anna Garuti, Giulia Buzzatti, Andrea Sciutto, Luca Arecco, Federico Villa, Franca Carli, Daniele Reverberi, Rodolfo Quarto, Mariella Dono, Lucia Del Mastro
Summary: This study investigates PIK3CA mutations in different circulating biomaterials and demonstrates the potential of these components to provide information on molecular targetable profiling. The consistent mutational profiles between extracellular vesicles and tumor cells suggest their association. This study also highlights the translational value of circulome in understanding the tumor heterogeneity.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Multidisciplinary Sciences
Oriana D'Ecclesiis, Costanza Gavioli, Chiara Martinoli, Sara Raimondi, Susanna Chiocca, Claudia Miccolo, Paolo Bossi, Diego Cortinovis, Ferdinando Chiaradonna, Roberta Palorini, Federica Faciotti, Federica Bellerba, Stefania Canova, Costantino Jemos, Emanuela Omodeo Sale, Aurora Gaeta, Barbara Zerbato, Patrizia Gnagnarella, Sara Gandini
Summary: A systematic review and analysis of the evidence on SARS-CoV2 infection and Covid-19 in relation to vitamin D deficiency and supplementation showed that vitamin D supplementation is associated with a lower risk of severe disease and mortality. The association is more significant in older individuals and at higher latitudes. Further randomized clinical studies are needed to confirm these findings.
Article
Medicine, General & Internal
Riccardo Orlandi, Francesca Bono, Diego Luigi Cortinovis, Giuseppe Cardillo, Ugo Cioffi, Angelo Guttadauro, Emanuele Pirondini, Stefania Canova, Enrico Mario Cassina, Federico Raveglia
Summary: Malignant Pleural Mesothelioma (MPM) is a highly aggressive disease with complex and challenging diagnosis. This study presents three unconventional cases and reviews relevant literature. Definitive biomarkers to distinguish MPM from other pleural affections are still needed.
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Medicine, General & Internal
Marina Elena Cazzaniga, Serena Capici, Nicoletta Cordani, Viola Cogliati, Francesca Fulvia Pepe, Francesca Riva, Maria Grazia Cerrito
Summary: This review summarizes the advantages and challenges of metronomic chemotherapy (mCHT) in preclinical and clinical settings. In preclinical studies, mCHT has a significant effect on the tumor microenvironment, but the direct effects on tumor cells are less clear. Key issues that need to be addressed include the lack of definition of an optimal biological dose, administration method, and validation of predictive biomarkers. In the clinical context, low toxicity is the most recognized advantage of mCHT, but the type of study design, lack of randomized trials, and uncertainty in terms of doses and drugs are still challenges.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Pharmacology & Pharmacy
Selena Russo, Marco Bani, Marco Terraneo, Valeria Quaglia, Giampaolo Nuvolati, Rebecca Cavaliere, Serena Capici, Marina Elena Cazzaniga, Maria Grazia Strepparava
Summary: The study conducted in Italy on the public register of healthy volunteers for COVID-19 vaccine clinical trials found that altruistic motivations were the main driver for enrollment. In-person and phone interviews showed good results in the recruitment process, while the email modality resulted in lower volunteer satisfaction and understanding.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
(2022)
Article
Critical Care Medicine
Chiara Robba, Francesca Graziano, Angelo Guglielmi, Paola Rebora, Stefania Galimberti, Fabio Taccone, Giuseppe Citerio, SYNAPSE-ICU Investigators
Summary: This study aims to describe the therapeutical approaches used in managing intracranial hypertension in acute brain injured patients and their association with six months mortality and neurological outcome. The results showed that therapies to control high ICP were frequently used during the first week of ICU admission, especially mild-moderate treatments. In some selected patients, the use of aggressive strategies may be beneficial for the six months mortality but not for neurological outcome.
INTENSIVE CARE MEDICINE
(2023)
Review
Oncology
Carlo Putzu, Stefania Canova, Panagiotis Paliogiannis, Renato Lobrano, Luca Sala, Diego Luigi Cortinovis, Francesca Colonese
Summary: Immunotherapy has significantly improved the outcomes of non-small cell lung cancer (NSCLC) patients, with more than 15% achieving long-term survival. This review aims to discuss the optimal duration of immunotherapy in long survivors to balance treatment efficacy and potential side effects, costs, and disease relapse or progression.
Article
Chemistry, Medicinal
Diego Luigi Cortinovis, Valentina Perrone, Elisa Giacomini, Diego Sangiorgi, Margherita Andretta, Fausto Bartolini, Giuseppe Taurino, Marco Belfiore, Emilia Sicari, Luca Degli Esposti
Summary: This study aimed to estimate the epidemiology and economic burden of early-stage non-small-cell lung carcinoma (eNSCLC) in the clinical practice Italian setting. An observational analysis was performed using administrative databases and revealed that about half of eNSCLC patients stage II-IIIA experienced a recurrence, with total direct costs of recurrence patients being almost two-fold those of no-recurrence patients.
Review
Biochemistry & Molecular Biology
Nicoletta Cordani, Tommaso Bianchi, Luca Carlofrancesco Ammoni, Diego Luigi Cortinovis, Marina Elena Cazzaniga, Andrea Alberto Lissoni, Fabio Landoni, Stefania Canova
Summary: Epithelial ovarian cancer (EOC), specifically high-grade serous carcinoma (HGSOC), is a leading cause of high death rates among gynecological cancers. Cytoreductive surgery and platinum-based chemotherapy are the main treatments for this aggressive disease. Molecular analysis has identified that up to 50% of HGSOC cases have deficiencies in the homologous recombination repair (HRR) system, making them sensitive to poly ADP-ribose inhibitors (PARP-is). However, drug resistance remains a challenge, and research is focused on combining PARP-is with antiangiogenic agents and immune checkpoint inhibitors. New drugs targeting different pathways are also in development.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Oncology
Stefania Canova, Benedetta Trevisan, Maria Ida Abbate, Francesca Colonese, Luca Sala, Alice Baggi, Sofia Paola Bianchi, Anna D'Agostino, Diego Luigi Cortinovis
Summary: The recent advances in the molecular knowledge of small cell lung cancer (SCLC) and potential new treatment strategies targeting DNA damage pathway, epigenetics, angiogenesis, and oncogenic drivers were reviewed. Addition of immunotherapy to chemotherapy has shown significant improvements in clinical outcomes, but the prognosis remains poor. Genomic alterations have been identified to classify SCLC into different molecular subtypes.
CURRENT ONCOLOGY REPORTS
(2023)
Review
Oncology
Cesare Gridelli, Marcello Tiseo, Diego Luigi Cortinovis, Maria Rita Migliorino, Vito Barbieri, Paolo Bironzo, Alessandra Bearz, Ilaria Attili, Filippo de Marinis
Summary: ALK tyrosine kinase inhibitors have significantly improved the treatment of NSCLC patients with ALK rearrangements. In Italy, Alectinib and brigatinib are the preferred first-line treatments, with lorlatinib pending approval. Age and performance status have little impact on treatment choice, but treatment compliance and toxicity profile should be considered. The treatment selection should take into account the patient's comorbidities and polypharmacotherapy interactions.
